Media Summary: Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the potential role of Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ... Dickon Hayne, MD, University of Western Australia, breaks down his team's study that investigated the safety and efficacy of ...

Bcg Combined With Mitomycin Offers Improved Adjuvant Treatment Regimen For High Risk Nmibc - Detailed Analysis & Overview

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the potential role of Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ... Dickon Hayne, MD, University of Western Australia, breaks down his team's study that investigated the safety and efficacy of ... Dr. Scott Gilbert on behalf of Moffitt Cancer Center in Tampa, FL speaks on recurrent Dr. Gary Steinberg MD discusses the management of Felix Guerrero-Ramos, MD, PhD, from Hospital Universitario 12 de Octubre in Madrid, Spain, provides insights into non-muscle ...

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, comments on the rapidly evolving landscape of ... Join us in this insightful episode as we delve into the latest advancements in the management of non-muscle-invasive bladder ... Leonard G. Gomella, MD, FACS, explores bladder cancer The Vattikuti Foundation teamed up with the International Bladder Cancer Group for a live Master Class on Feb. 27, 2021: ... Brant A. Inman, MD, MS, FRCSC, Chin-Hardie Chair of Urologic Oncology and Professor of Urology and Oncology, Western ... Trinity J. Bivalacqua, MD, PhD, Director of Urologic Oncology

Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the continued importance of ... In this video, Mr Raj Nair, Consultant Urological Surgeon answers the most common questions around Roger Li, MD, of Moffitt Cancer Center, details the final results of CORE-001, a phase-2, single arm study of cretostimogene ... Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus ...

Photo Gallery

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC
Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC
Sasanlimab BCG combo improves outcomes in high-risk NMIBC
Treatment of High-Risk NMIBC: Is BCG Still the Best Option?
Efficacy, Safety of Mitomycin Plus BCG for Patients With High-Risk NMIBC
IVUmed VVP: Recurrent NMIBC and BCG Unresponsive Disease
Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series
A Better Treatment than BCG for Bladder Cancer?
High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies
Managing NMIBC in the BCG Shortage Era
The rapidly eolving landscape for high-risk non-muscle invasive bladder cancer treatment
Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer
Sponsored
Sponsored
View Detailed Profile
BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

Dr Hayne talks to ecancer

Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC

Evaluating intravesical chemotherapy and BCG for enhanced outcomes in NMIBC

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the potential role of

Sponsored
Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Dr Powles talks to ecancer

Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Treatment of High-Risk NMIBC: Is BCG Still the Best Option?

Neal Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, South Carolina, reviews whether ...

Efficacy, Safety of Mitomycin Plus BCG for Patients With High-Risk NMIBC

Efficacy, Safety of Mitomycin Plus BCG for Patients With High-Risk NMIBC

Dickon Hayne, MD, University of Western Australia, breaks down his team's study that investigated the safety and efficacy of ...

Sponsored
IVUmed VVP: Recurrent NMIBC and BCG Unresponsive Disease

IVUmed VVP: Recurrent NMIBC and BCG Unresponsive Disease

Dr. Scott Gilbert on behalf of Moffitt Cancer Center in Tampa, FL speaks on recurrent

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Treatment of high risk nMIBC in era of BCG shortage - EMPIRE Urology Lecture Series

Dr. Gary Steinberg MD discusses the management of

A Better Treatment than BCG for Bladder Cancer?

A Better Treatment than BCG for Bladder Cancer?

BCG

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapies

Felix Guerrero-Ramos, MD, PhD, from Hospital Universitario 12 de Octubre in Madrid, Spain, provides insights into non-muscle ...

Managing NMIBC in the BCG Shortage Era

Managing NMIBC in the BCG Shortage Era

Seth P. Lerner, MD, explains the

The rapidly eolving landscape for high-risk non-muscle invasive bladder cancer treatment

The rapidly eolving landscape for high-risk non-muscle invasive bladder cancer treatment

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, comments on the rapidly evolving landscape of ...

Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

Immunotherapy Plus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

Join us in this insightful episode as we delve into the latest advancements in the management of non-muscle-invasive bladder ...

Intermediate Risk NMIBC BCG Naïve Treatment of Choice with Dr. Leonard G. Gomella, MD, FACS

Intermediate Risk NMIBC BCG Naïve Treatment of Choice with Dr. Leonard G. Gomella, MD, FACS

Leonard G. Gomella, MD, FACS, explores bladder cancer

Evolving Role of BCG in Non-Muscle Invasive Bladder Cancer-Myths & Facts

Evolving Role of BCG in Non-Muscle Invasive Bladder Cancer-Myths & Facts

The Vattikuti Foundation teamed up with the International Bladder Cancer Group for a live Master Class on Feb. 27, 2021: ...

Treatment of Bladder Cancer: Therapies Beyond BCG for NMIBC

Treatment of Bladder Cancer: Therapies Beyond BCG for NMIBC

Brant A. Inman, MD, MS, FRCSC, Chin-Hardie Chair of Urologic Oncology and Professor of Urology and Oncology, Western ...

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials

Trinity J. Bivalacqua, MD, PhD, Director of Urologic Oncology

The role of BCG in treating high-risk non-muscle invasive bladder cancer

The role of BCG in treating high-risk non-muscle invasive bladder cancer

Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the continued importance of ...

BCG Treatment: Frequently Asked Questions

BCG Treatment: Frequently Asked Questions

In this video, Mr Raj Nair, Consultant Urological Surgeon answers the most common questions around

Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS #bladdercancer #cancer #news

Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS #bladdercancer #cancer #news

Roger Li, MD, of Moffitt Cancer Center, details the final results of CORE-001, a phase-2, single arm study of cretostimogene ...

Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC

Introduction to Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC

Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, talks about this new adenovirus ...